Cardio Diagnostics (CDIO) Competitors

OncoCyte (NASDAQ:OCX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Does the MarketBeat Community believe in OCX or CDIO?

OncoCyte received 2 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 66.67% of users gave Cardio Diagnostics an outperform vote while only 6.90% of users gave OncoCyte an outperform vote.

Company	Underperform	Outperform
OncoCyte	Outperform Votes 4 6.90%	Underperform Votes 54 93.10%
Cardio Diagnostics	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%

Which has more volatility and risk, OCX or CDIO?

OncoCyte has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 5.03, indicating that its share price is 403% more volatile than the S&P 500.

Which has higher earnings and valuation, OCX or CDIO?

Cardio Diagnostics has lower revenue, but higher earnings than OncoCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OncoCyte	$1.50M	13.78	-$27.78M	N/A	N/A
Cardio Diagnostics	$20K	939.17	-$8.38M	N/A	N/A

Do analysts prefer OCX or CDIO?

OncoCyte currently has a consensus target price of $3.90, suggesting a potential upside of 56.00%. Given Cardio Diagnostics' higher possible upside, equities research analysts clearly believe OncoCyte is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OncoCyte	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardio Diagnostics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in OCX or CDIO?

55.4% of OncoCyte shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.9% of OncoCyte shares are owned by company insiders. Comparatively, 30.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is OCX or CDIO more profitable?

Cardio Diagnostics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -3,923.58%. Cardio Diagnostics' return on equity of -77.26% beat OncoCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OncoCyte	-3,923.58%	-77.26%	-33.66%
Cardio Diagnostics	N/A	-293.34%	-131.96%

Does the media prefer OCX or CDIO?

In the previous week, OncoCyte had 14 more articles in the media than Cardio Diagnostics. MarketBeat recorded 15 mentions for OncoCyte and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.21 beat OncoCyte's score of 0.00 indicating that OncoCyte is being referred to more favorably in the media.

Company	Overall Sentiment
OncoCyte	Neutral
Cardio Diagnostics	Neutral

Summary

OncoCyte beats Cardio Diagnostics on 8 of the 15 factors compared between the two stocks.